Biodexa Pharmaceuticals (BDRX) Trading Income (2013 - 2025)

Biodexa Pharmaceuticals (BDRX) posted Trading Income of $3990.5 for Q4 2025, little changed sequentially from $4002.1 in Q2 2025.

Biodexa Pharmaceuticals (BDRX) Trading Income (2013 - 2025) Analysis & Trends

Biodexa Pharmaceuticals has reported Trading Income for 9 years, with the latest figure at $3990.5 in Q4 2025.

Quarterly Trading Income changed N/A year-over-year to $3990.5 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3990.5 (changed N/A YoY) and the FY2025 annual result came in at -$205.3 million, changed N/A from the prior year.
Trading Income was little changed at $3990.5 in Q4 2025 per BDRX's latest filing, from $4002.1 in the prior quarter.
Over five years, Trading Income peaked at $4002.1 in Q2 2025 and troughed at $3990.5 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Trading Income (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Biodexa Pharmaceuticals	64,325.41	-11.29 Mn	-	-

Download Data